Paris-Based baCta Secures €7 Million in Seed Funding
baCta, a Paris-based biotech company, has successfully raised €7 million in a Seed funding round. The company, founded by Mathieu Nohet, focuses on producing industrial ingredients through precision fermentation, aiming for sustainable abundance. Their first product, b-Astaxanthin, is set to benefit from this new influx of capital.
Investors and Funding Details
The Seed round was led by LocalGlobe and Daphni, with additional participation from OVNI Capital, Phagos, Genomines, and Mistral AI. This diverse group of investors highlights the growing interest in AI-driven bioproduction.
AI-Powered Bioproduction
baCta leverages a combination of artificial intelligence, synthetic biology, and precision fermentation to transform microorganisms into programmable molecular factories. This approach allows for the efficient and sustainable production of various industrial ingredients. Mathieu Nohet, the founder and CEO, stated: "We are entering a new era where microorganisms can be used as programmable molecular factories to synthesize organic molecules profitably at commercial scale."
Purpose of the Funding
The funds will primarily support the industrial scale-up of baCta’s first product, b-Astaxanthin, an antioxidant. Additionally, the company plans to accelerate the deployment of baCtaForge, its strain engineering platform. This platform combines a precision biofoundry with a genome-to-factory AI model, further enhancing its production capabilities.
Future Prospects
With this funding, baCta aims to demonstrate the value of its unique AI-driven approach, proving that it can make the supply of industrial ingredients both resilient and abundant. As demand for such ingredients grows, baCta is well-positioned to offer a sustainable alternative to conventional production methods.
Located in Paris, Île-de-France, baCta is at the forefront of the biotech industry, pushing the boundaries of what is possible with AI and biotechnology.